BackProtagenic Therapeutics Overview

Protagenic Therapeutics Current Assets

Track Protagenic Therapeutics's current assets ($2.3M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$2.30M
22.10% YoYΔ $416170.00 vs prior year quarter

Peer average

Loading

Protagenic Therapeutics Current Assets History

Loading

Protagenic Therapeutics vs. peers: Current Assets Comparison

Loading

Protagenic Therapeutics Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Protagenic Therapeutics (PTIX) FAQ

Protagenic Therapeutics posts a current assets of $2.3M as of December 2025. That compares with $1.9M in the prior-year period — up 22.1% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Protagenic Therapeutics's current assets was $1.9M. The latest reading is $2.3M — a 22.1% year-over-year increase (period ending December 2025). Use the history and growth charts on this page for a longer lookback.

Current Assets is one piece of Protagenic Therapeutics's financial statement story. At $2.3M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for PTIX's current assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Protagenic Therapeutics's other metric pages and overview cover the third.

Judging Protagenic Therapeutics against Industrials peers is usually better than using a market-wide rule of thumb. Business models inside Industrials are more comparable, which makes gaps in current assets easier to interpret. Start with $2.3M here, then scan peer and history charts to see if the gap is persistent.